论文部分内容阅读
长效胰高血糖素样肽1,在高血糖时促进胰岛素的分泌,提高β细胞的数量及功能,减少胰高血糖素分泌、延迟胃排空、减少餐后高血糖、减轻体质量等,但半衰期太短限制了其应用通过结构改造得到的胰高血糖素样肽1类似物利拉鲁肽,通过按需调节胰岛素和胰高血糖素分泌降低血糖,减弱了普通降糖药物的过量导致的低血糖反应。由于其强效、长效、不良反应轻、患者耐受性好等特点,有可能成为一种极有前景的治疗2型糖尿病药物。
Long-acting glucagon-like peptide 1, promote insulin secretion during hyperglycemia, improve the number and function of β cells, reduce glucagon secretion, delay gastric emptying, reduce postprandial hyperglycemia, reduce body weight, However, its short half-life limits its application to the structurally modified glucagon-like peptide 1 analog liraglutide, which reduces blood glucose by regulating insulin and glucagon secretion as needed, attenuating the excess of common hypoglycemic agents Hypoglycemia reaction. Because of its strong, long-lasting, mild adverse reactions, patient tolerance and other characteristics may become a promising treatment of type 2 diabetes drugs.